{
    "clinical_study": {
        "@rank": "5082", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and effectiveness of taking lamivudine\n      (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV\n      combination tablet (Combivir) plus a PI. This study also examines how well patients follow\n      the dosing schedules for these drugs.\n\n      Doctors believe that taking Combivir plus a PI may be as effective as taking 3TC plus ZDV\n      plus a PI."
        }, 
        "brief_title": "A Study of Two Anti-HIV Drug Combinations", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is hypothesized that a fixed-dose 3TC/ZDV tablet given bid in combination with a protease\n      inhibitor is clinically equivalent in its effect on plasma HIV-1 RNA level to a conventional\n      regimen of 3TC, ZDV, and a protease inhibitor.\n\n      Patients are stratified according to their current protease inhibitor therapy and randomized\n      to receive open-label therapy of 1 Combivir tablet bid (Arm II) or an equivalent dose of 3TC\n      and ZDV (Arm I), plus their current protease inhibitor for 16 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection documented by a licensed antibody ELISA assay and confirmed by Western\n             blot, positive HIV blood culture, positive HIV serum antigen, or plasma viremia.\n\n          -  CD4+ cell count of at least 300 cells/mm3.\n\n          -  HIV-1 RNA less than 10,000 copies/ml by Roche Amplicor PCR assay.\n\n          -  CDC Category A or B Classification for HIV infection  (no clinical diagnosis of\n             AIDS).\n\n          -  Compliance with dosing schedule and protocol evaluations.\n\n        Prior Medication:\n\n        Required:\n\n          -  3TC at 150 mg bid, ZDV at 600 mg/day (200 mg tid or 300 mg bid), plus a marketed\n             protease inhibitor (ritonavir, saquinavir, indinavir, or nelfinavir) at its\n             recommended dose for at least 10 weeks.\n\n        Allowed:\n\n          -  Inhaled corticosteroids for the treatment of asthma.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malabsorption syndromes affecting drug absorption (e.g., Crohn's disease and chronic\n             pancreatitis).\n\n          -  Enrollment in other investigational protocols.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Cytotoxic chemotherapeutic agents.\n\n          -  Nonnucleoside reverse transcriptase inhibitors.\n\n          -  Other investigational agents.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiation therapy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Cytotoxic chemotherapeutic and immunomodulating agents such as systemic\n             corticosteroids, IF-2, alpha-IFN, beta-IFN, or gamma-IFN (except for inhaled\n             corticosteroids for the treatment of asthma) within 4 weeks of study entry.\n\n          -  HIV immunotherapeutic vaccine within 3 months of study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Radiation therapy within 4 weeks of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002203", 
            "org_study_id": "280A", 
            "secondary_id": "NZTA4001"
        }, 
        "intervention": [
            {
                "intervention_name": "Lamivudine/Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "HIV Protease Inhibitors", 
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Lamivudine, zidovudine drug combination", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "HIV Protease Inhibitors", 
            "CD4 Lymphocyte Count", 
            "CD4-CD8 Ratio", 
            "Lamivudine", 
            "Patient Compliance", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Pacific Oaks Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Tower Infectious Diseases / Med Associates Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ of North Carolina Hosps"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28232"
                    }, 
                    "name": "Carolinas Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annandale", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22003"
                    }, 
                    "name": "Infectious Diseases Physicians Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "Univ of Wisconsin School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santurce", 
                        "country": "Puerto Rico", 
                        "zip": "00907"
                    }, 
                    "name": "San Juan AIDS Program"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002203"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Carolinas Med Ctr": "35.227 -80.843", 
        "Infectious Diseases Physicians Inc": "38.83 -77.196", 
        "Pacific Oaks Med Ctr": "34.074 -118.4", 
        "San Juan AIDS Program": "18.441 -66.047", 
        "Tower Infectious Diseases / Med Associates Inc": "34.052 -118.244", 
        "Univ of North Carolina Hosps": "35.913 -79.056", 
        "Univ of Wisconsin School of Medicine": "43.073 -89.401"
    }
}